Oppenheimer Initiates Coverage On Keros Therapeutics with Outperform Rating, Announces Price Target of $102
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer has initiated coverage on Keros Therapeutics (NASDAQ:KROS) with an Outperform rating and a price target of $102.
June 25, 2024 | 9:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer has initiated coverage on Keros Therapeutics with an Outperform rating and a price target of $102.
The initiation of coverage with an Outperform rating and a high price target of $102 by a reputable firm like Oppenheimer is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100